-
Oncolytic viruses in cancer treatment
Suzanne Elvidge
April 21, 2025
Naturally occurring oncolytic viruses, which replicate in tumour cells and trigger apoptosis and immune responses while sparing healthy cells, were first discovered at the turn of the 19th century.
-
Ascentage Pharma and MD Anderson Cancer Center Announce Strategic Alliance in Cancer Drug Development
pharmafocusasia
January 09, 2019
Ascentage Pharma Group, Inc., and The University of Texas MD Anderson Cancer Center today announced a five-year strategic collaboration agreement to advance the development of five potential new cancer therapies.....
-
GSK to acquire cancer therapeutics firm Tesaro for $5.1bn
pharmaceutical-technology
December 05, 2018
GlaxoSmithKline (GSK) has signed a merger agreement to buy US-based biopharmaceutical company Tesaro for an aggregate consideration of around $5.1bn in a cash-based transaction......
-
Selvita to Present New Data from SEL120 Program at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
b3cnewswire
November 10, 2018
The presentation during the symposium will feature preclinical data from Selvita’s CDK8 inhibitor program SEL120 - potential treatment of acute myeloid and lymphoblastic leukemias. SEL120 is the most advanced, fully-owned oncology program in company’s pip
-
Selvita to Present New Data from SEL120 Program at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
b3cnewswire
November 10, 2018
The presentation during the symposium will feature preclinical data from Selvita’s CDK8 inhibitor program SEL120 - potential treatment of acute myeloid and lymphoblastic leukemias. SEL120 is the most advanced, fully-owned oncology program in company’s pip
-
Affimed signs up to $5bn cancer therapeutics deal with Genentech
pharmaceutical
August 30, 2018
German biopharmaceutical firm Affimed has signed a collaboration agreement with Roche unit Genentech to develop and commercialise immunotherapeutics targeting a variety of cancers.